Press Releases
June 8, 2026
Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia
Read more
Targeted Glue™ degraders, precision medicines
Scroll to continueAmphista Therapeutics® is redefining Targeted Protein Degradation. Our proprietary Targeted Glues™ go beyond traditional CRBN-based approaches, deploying novel E3 ligases, optimized for each target. Built for precision. Driven to deliver transformational medicines.
Engineering precision degraders
Target first discovery
We focus on high-value therapeutic targets where degradation offers clear superiority over other modalities.
The right ligase
We allow the target to choose its most efficient E3 ligase, leveraging the cell’s natural biology to identify optimal degradation pathways.
An integrated discovery and clinical team
Leveraging the power of world class scientists, colocated in Cambridge UK.
Impacting patients
We are advancing a robust pipeline of Targeted Glues™ against high-value targets. Our lead program, AMX-883,
a first in class DCAF16-mediated BRD9 degrader for acute myeloid leukaemia, will enter the clinic in 2026.
Our news
Press Releases
April 24, 2026
Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program
Read more
Press Releases
April 21, 2026
Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
Read more